Quality of life on treatment with metoprolol in dilated cardiomyopathy: Results from the MDC trial

Cardiovascular Drugs and Therapy

Volumn 10, Issue 3, 1996, Pages 361-368

  Wiklund, I ^a   Waagstein, F ^b   Swedberg, K ^b   Hjalmarsson, A ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

Beta blockers; Dilated cardiomyopathy; Heart failure; Metoprolol; Quality of life

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; METOPROLOL;

ADULT; ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; EMOTION; FEMALE; HEART DILATATION; HEART FUNCTION; HEART TRANSPLANTATION; HUMAN; LIFE SATISFACTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; WELLBEING;

ADRENERGIC BETA-ANTAGONISTS; CARDIOMYOPATHY, DILATED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METOPROLOL; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; STROKE VOLUME; TREATMENT OUTCOME;

EID: 0029738922     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Wenger NK. Assessment of quality of life: A medical imperative. Cardiovasc Drugs Ther 1988;1:553-558.
2. Wenger NK. Quality of life: Can it and should it be assessed in patients with heart failure? Cardiology 1989;76:391-398.
3. Waagstein F, Hjalmarson A, Varnauskak E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1036.
4. Eichhorn EJ. The paradox of beta-adrenergic blockade for the management of congestive heart failure. Am J Med 1992;92:527-538.
5. Hjalmarson Å, Waagstein F. The role of beta-blockers in the treatment of cardiomyopathy and ischaemic heart failure. Drugs 1994:47(Suppl 4):31-40.
6. Engelmeier RS, O'Connell JB, Walsh R, Rad N, Scanlon PJ, Gunnar RM. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: A double-blind, randomized, placebo-controlled trial. Circulation 1985;72:536-546.
7. Nemanich JW, Veith RC, Abrass IB, Stratton JR. Effects of metoprolol on rest and exercise cardiac function and plasma catecholamines in chronic congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. Am J Cardiol 1990;66:843-848.
8. Olsson G, Wikstrand J, Warnold I, et al. Metoprolol-induced reduction in postinfarction mortality: Pooled results from five double-blind randomized trials. Eur Heart J 1992; 13:28-32.
9. Olsson G, Tuomilehto J, Berglund G, et al. Primary prevention of sudden cardiovascular death in hypertensive patients: Mortality results from the MAPHY study. Am J Hypertens 1991;4:151-158.
10. Wikstrand J, Warnold I, Tuomilehto J, et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension 1991;17:579-588.
11. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441-1446.
12. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-381.
13. Patterson JA, Naughton J, Pietras RJ, Gunnar RM. Treadmill exercise in assessment of functional capacity of patients with cardiac disease. Am J Cardiol 1972;30:757-762.
14. Wiklund I, Lindvall K, Swedberg K, Zupkis RV. Self-assessment of quality of life in severe heart failure. Scand J Psychol 1987;28:220-225.
15. Sharpe DN, Murphy J, Coxon R, Hannan SF. Enalapril in patients with chronic heart failure: A placebo-controlled, randomized, double-blind study. Circulation 1984;70:271-278.
16. Barnett DB. Assessment of quality of life. Am J Cardiol 1991;67:41C-44C.
17. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J 1992;124:1017-1025.
18. Guyatt GH. Measurement of health-related quality of life in heart failure. J Am Coll Cardiol 1993;22(Suppl A):185A-191A.
19. Cowley AJ, Skene AM. Treatment of severe heart failure: Quantity or quality of life? A trial of enoximone. Br Heart J 1994;72:226-230.
20. Blackwood R, Mayou RA, Garnham JC, Armstrong C, Bryant B. Exercise capacity and quality of life in the treatment of heart failure. Clin Pharmacol Ther 1990;48:325-332.
21. Kubo SH, Gollub S, Bourge R, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group. Circulation 1992;85:942-949.
22. Massie BM, Berk MR, Brozena SC, et al. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET). Circulation 1993;88:492-501.
23. Rector TS, Johnson G, Dunkman WB, et al. Evaluation by patients with heart failure of the effects of enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. Circulation 1993;87:VI-71-VI-77.
24. Rogers WJ, Johnstone DE, Yusuf S, et al. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: The Studies of Left Ventricular Dysfunction. The SOLVD Investigators. J Am Coll Cardiol 1994;23:393-400.
25. Just H, Drexler H, Taylor SH, Siegrist J, Schulgen G, Schumacher M. Captopril versus digoxin in patients with coronary artery disease and mild heart failure. A prospective, double-blind, placebo-controlled multicenter study. The CADS Study Group. Herz 1993;18(Suppl 1):436-443.
26. 10 as an adjunctive in the treatment of chronic congestive heart failure. Heart Failure 1996, in press.
27. Rector TS, Kubo SH, Cohn JN. Patients' self-assessment of their congestive heart failure: Content, reliability and validity of a new measure - the Minnesota Living with Heart Failure questionnaire. Heart Failure 1987;3:198-209.
28. Grady KL. Quality of life in patients with chronic heart failure. Crit Care Nursing Clin North Am 1993;5:661-670.
29. Mayou R, Blackwood R, Bryant B, Garnham J. Cardiac failure: Symptoms and functional status. J Psychosom Res 1991;35:399-407.
30. Hjemdahl P, Wiklund I. Quality of life on antihypertensive drug therapy: Scientific endpoint or marketing exercise? Hypertension 1992;10:1437-1446.
31. Gilligan DM, Chan WL, Joshi J, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;21:1672-1679.
32. Swedberg K, Hjalmarson Å, Waagstein F, Wallentin I. Beneficial effects of long-term β-blockade in congestive cardiomyopathy. Br Heart J 1980;44:117-133.